This is a cohort study aimed at developing a stratified medicine approach for personalised neoadjuvant chemotherapy (NCT) in high-risk soft tissue sarcoma (STS) patients with dedifferentiated liposarcoma (DDLPS), leiomyosarcoma (LMS), synovial sarcoma (SS), vascular sarcomas, malignant peripheral nerve sheath tumour (MPNST) or other subtypes. It comprises of both retrospective and prospective tissue collection from patients advancing directly to surgery (control group) and patients receiving NCT and surgery.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Identify a difference in expression profiles, using proteomics, genomics, epigenomics, in tissue samples obtained pre- and post-NCT and post-surgery alone
Timeframe: Through study completion, average 4 years
Develop an understanding of radiomic profiles for patients treated with NCT.
Timeframe: Through study completion, average 4 years
Develop an electronic STS Tissue Atlas for 5 high risk subtypes.
Timeframe: Through study completion, average 4 years
Develop and characterize patient derived models to investigate biology of high-risk sarcomas and directly test predicted therapeutic interventions
Timeframe: Through study completion, average 4 years
Develop a nomogram app to predict benefit of NCT and predict risk of recurrence.
Timeframe: Through study completion, average 4 years